Detailed review on Bevacizumab and its target therapies

Ankit Kumar 1, S P Srinivas Nayak 1, * and Ronit Kumar Arvind 2

1 Department of Pharmacy Practice, Parul Institute of Pharmacy, Parul University, Vadodara, Gujarat, India, 391760.
2 Clinical pharmacology, Paras HEC hospital, Dhurwa, Ranchi, Jharkhand, India 834004.
 
Review
Open Access Research Journal of Biology and Pharmacy, 2023, 09(01), 027–031.
Article DOI: 10.53022/oarjbp.2023.9.1.0042
Publication history: 
Received on 28 August 2023; revised on 04 October 2023; accepted on 06 October 2023
 
Abstract: 
The review in this article focuses on bevacizumab, an agent widely used in a variety of treatment strategies. It provides an overview of the pharmacokinetics and pharmacodynamics of bevacizumab, with a focus on intravenous administration and available specific dose strengths. This article discusses treatment strategies with bevacizumab and emphasizes the importance of understanding its pharmacokinetic properties to optimize its efficacy. In addition, this review covers a wide range of side effects associated with bevacizumab, including cardiovascular, gastrointestinal, hematological, immune, musculoskeletal, nervous, renal, respiratory, and other side effects. The importance of close monitoring and prompt management of adverse events is emphasized to ensure patient safety and optimize patient outcomes. Overall, this literature review provides valuable insight into the use of bevacizumab and helps health professionals make informed decisions regarding dosing, monitoring, and management of side effects.
 
Keywords: 
Bevacizumab; Pharmacokinetics; Pharmacodynamics; Therapeutic strategy; Adverse reaction.
 
Full text article in PDF: